Atagabalin

CAS No. 223445-75-8

Atagabalin( PD 0200390 )

Catalog No. M13581 CAS No. 223445-75-8

Atagabalin (PD 0200390) is a novel ligand of the voltage-dependent calcium channel (VDCC) α2δ subunit (1 and 2) for treatment for insomnia.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 873 Get Quote
50MG 1782 Get Quote
100MG 2250 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Atagabalin
  • Note
    Research use only, not for human use.
  • Brief Description
    Atagabalin (PD 0200390) is a novel ligand of the voltage-dependent calcium channel (VDCC) α2δ subunit (1 and 2) for treatment for insomnia.
  • Description
    Atagabalin (PD 0200390) is a novel ligand of the voltage-dependent calcium channel (VDCC) α2δ subunit (1 and 2) for treatment for insomnia.Sleep Disorder Phase 2 Discontinued.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    PD 0200390
  • Pathway
    GPCR/G Protein
  • Target
    Calcium Channel
  • Recptor
    Calcium Channel
  • Research Area
    Neurological Disease
  • Indication
    Sleep Disorder

Chemical Information

  • CAS Number
    223445-75-8
  • Formula Weight
    185.267
  • Molecular Formula
    C10H19NO2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C(O)CC1(CN)C[C@H](C)[C@@H](C)C1
  • Chemical Name
    2-((3S,4S)-1-(aminomethyl)-3,4-dimethylcyclopentyl)acetic acid

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Blakemore DC, et al. Bioorg Med Chem Lett. 2010 Jan 15;20(2):461-4. 2. Quintero JE, et al. Brain Res. 2011 Jul 15;1401:1-9.
molnova catalog
related products
  • Dipsacoside B

    Dipsacoside B is a major bioactive saponin used as a marker.

  • Isradipine

    Isradipine is a potent and selective L-type voltage-gated calcium channel blocker, used to treat high blood pressure.

  • Yangambin

    Yangambin is a selective antagonist of the cardiovascular effects of platelet activating factor (PAF); it has hypotensive effect, which is probably due to a peripheral vasodilatation that involves, at least, the inhibition the Ca2+ influx through voltage-gated Ca2+ channels. Yangambin has central nervous system activity, it presents a depressant activity in the open field, forced swimming and pentobarbital sleeping time tests.